Successful seasonal flu vaccine development depends on protecting the world's population against the top 3-4 strains that are expected to be in circulation for the flu season. Keeping track of the flu requires a combination of precision tools, carefully managed processes and high caliber scientific and regulatory expertise.
Download our insight brief and learn 6 critical ways to keep track of the flu to optimize your seasonal flu vaccine development clinical trials. IQVIA Laboratories' experts understand the critical success factors to support your needs for the development of safe and effective vaccines in time to protect people from seasonal flu.
Authors:
Wayne Hogrefe, Ph.D., D (ABMLI), Vice President, IQVIA Laboratories
Sorika van Niekerk MSc, UP, SA, Senior Director, IQVIA Laboratories
Ayaskant Pany, M.D., Director, IQVIA Laboratories
Complete the form below to access this insight brief
Related Insights
How COVID-19 Changed Clinical Trial Dynamics and Environment
Precision Medicine World Conference 2021 Virtual Presentation
Vaccine Laboratory Services
Test Menu
SARS-CoV-2 Vaccine Induced Antibody Profiles
Presented at World Vaccine Congress 2021
Vaccine Testing for SARS-CoV-2
ELISA and Viral Neutralization Assays
Vaccine Laboratory Services
Combating Emerging and Re-Emerging Infectious Diseases in Clinical Trials by Harnessing Innovative Technologies
Harnessing innovative technologies for clinical trials involving emerging and re-emerging infectious diseases
Tools for better management of infectious disease clinical trials
Zika Vaccine Research: Complex Steps Toward a Critical Need
Overcoming Zika vaccine development challenges
Vaccine Testing Capabilities
End-to-end laboratory for clinical vaccine development
IQVIA Laboratories Corporate Brochure
A global drug discovery and development laboratory services organization
